Bionano OGM detects 97.8% T-ALL abnormalities, nearly double conventional methods
Bionano Genomics announced the publication of a peer-reviewed study in Modern Pathology demonstrating that its optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases. This detection rate is nearly double the 55% achieved by conventional cytogenetic analysis. Conducted by researchers at MD Anderson Cancer Center and Johns Hopkins University School of Medicine, the 91-subject study highlighted OGM's ability to provide additional genomic insights beyond standard methods in approximately 70% of cases, including 21 newly identified gene fusions. The findings underscore OGM's potential to transform the study and understanding of this aggressive blood cancer and streamline genomic analysis workflows.
Key Highlights
- OGM detected genomic abnormalities in 97.8% of T-ALL cases, nearly double the 55% detection rate of conventional cytogenetic analysis.
- OGM provided additional genomic insights beyond standard methods in approximately 70% of cases.
- The study analyzed 91 T-ALL cases, making it the largest OGM study of T-ALL to date.
- OGM identified 24 known recurrent gene fusions and 21 newly identified fusions, detecting rearrangements in 80% of cases.
- OGM identified copy number changes in 93% of cases, while NGS detected sequence variants in 92% of cases.
- The gene most frequently found to harbor variants was NOTCH1 (57% of cases).
Price Impact
More from BNGO